Group 1: ETF Performance - As of January 21, the Medical Equipment ETF (159873) saw a net subscription of 3 million units, with a turnover rate of 8.04% and a transaction volume of 18.88 million yuan [1] - The Medical Equipment ETF reached a new high with a total size of 379 million units [1] - The Medical Equipment ETF has experienced continuous net inflows over the past 10 days, totaling 119 million yuan [1] Group 2: Innovation Drug ETF Highlights - The Innovation Drug ETF Tianhong (517380) achieved a new size of 1.88 billion yuan and a total of 2.36 billion units, both marking new highs since its inception [2] - The Innovation Drug ETF has seen continuous net inflows for 12 days, accumulating 426 million yuan [3] Group 3: Market Trends and Events - A new guideline was released by the National Healthcare Security Administration on January 20, focusing on pricing for surgical robots and other medical services, establishing 37 pricing projects and 5 additional items [6] - The JPM 2026 conference highlighted the strength of Chinese innovative drugs, with significant collaborations between Chinese companies and multinational giants, indicating a shift from asset export to global participation [7] Group 4: Institutional Insights - According to Founder Securities, the implementation of the new pricing guideline will promote the clinical adoption of innovative technologies and drive demand for terminal equipment and surgical assistance [8] Group 5: Product Features - The Medical Equipment ETF (159873) has a high content of brain-computer interface stocks, accounting for over 19%, and includes nearly 80% of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market [4]

Market Overview - The Hong Kong stock market opened higher on January 22, with the Hang Seng Index rising by 0.62% to 26,750.51 points, the Hang Seng Tech Index increasing by 0.85% to 5,795 points, and the National Enterprises Index up by 0.55% to 9,173.54 points [1] - Major tech stocks mostly rose, with Alibaba up 1.72%, Tencent Holdings up 0.33%, JD Group up 0.98%, and Xiaomi Group up 0.9% [1] - Chip stocks opened high, with Zhaoyi Innovation rising over 7% [1] - The innovative drug concept was active, with WuXi Biologics rising over 1% [1] - Gold stocks generally fell, with Shandong Gold down over 2% [1] - Longqi Technology's IPO on the Hong Kong stock market saw a nearly 13% increase on its first day [1] Company News - Shanghai Electric (02727.HK) expects a net profit of RMB 1.1 billion to RMB 1.32 billion for 2025, an increase of approximately 47% to 76% year-on-year [2] - Kingdee International (00268.HK) anticipates total revenue of approximately RMB 6.95 billion to RMB 7.05 billion for 2025, a year-on-year growth of about 11.1% to 12.7% [2] - Beijing Machinery Electric (00187.HK) expects a net loss of RMB 46 million to RMB 55.2 million for 2025, primarily due to intensified international trade frictions affecting its gas storage and transportation export business [2] - Chow Tai Fook (01929.HK) reported a retail value growth of 17.8% for the three months ending December 31, 2025, with mainland China retail value increasing by 16.9% [2] - Zai Lab (09911.HK) anticipates a cumulative download of approximately 970 million for its social business by 2025, a year-on-year increase of about 5.9% [2] Strategic Developments - Ruiri Medical Technology (01696.HK) signed a letter of intent for cooperation with Stryker Medical to establish localized production in China [3] - Cathay Pacific (00293.HK) and Hong Kong Express expect to carry over 36 million passengers in 2025, a year-on-year increase of 27% [4] - Shenyang Public Development (00747.HK) has initiated edge computing infrastructure and service business [5] - Flat Glass Group (06865.HK) plans to absorb and merge with Zhongda Quartz Development [6] Share Buybacks - Xiaomi Group (01810.HK) repurchased 7 million shares for HKD 248 million at prices between HKD 35.22 and HKD 35.48 [7] - Pop Mart (09992.HK) repurchased 500,000 shares for HKD 96.49 million at prices between HKD 191.1 and HKD 194.9 [8] - Sunny Optical Technology (02382.HK) repurchased 970,000 shares for HKD 61.39 million at prices between HKD 62.30 and HKD 63.95 [9] - Geely Automobile (00175.HK) repurchased 2.376 million shares for HKD 39.62 million at prices between HKD 16.62 and HKD 16.81 [10] Financial Instruments - Huaneng International Power (00902.HK) completed the issuance of RMB 2 billion medium-term notes [11] - CICC (03908.HK) plans to issue up to RMB 5 billion in bonds for technology innovation companies [12] Institutional Insights - Dongwu Securities noted that despite a general reduction in the Fed's interest rate cut expectations in overseas markets, domestic investors remain optimistic [13] - Orient Securities highlighted that recent U.S. measures against Venezuela and Greenland have increased geopolitical risks, supporting gold prices [14] - Zheshang Securities suggested that the humanoid robot sector has formed an ecological closed loop, recommending attention to component suppliers and undervalued transformation targets [14] - CITIC Securities indicated that new policies from the National Medical Insurance Administration will accelerate the promotion of surgical robots in China [14]

Core Insights - The report highlights significant investments made by fund manager Xie Zhiyu in various technology sectors, particularly in overseas computing power and semiconductor equipment, indicating a strategic focus on high-growth areas for 2026 [1][2] Investment Strategy - The funds managed by Xie Zhiyu, namely Xingquan He Yi and Xingquan He Run, have newly increased their positions in companies such as Baiwei Storage, Huiliang Technology, and WuXi Biologics, while also increasing their holdings in CATL [1] - The report emphasizes the importance of tracking core competitive trends in companies over a longer cycle to identify investment opportunities arising from technological transformations and sectoral rebounds [2] Sector Performance - The overseas computing power sector, particularly in optical modules, is experiencing record highs due to increased orders from major clients and advancements in new technologies [1] - Domestic supply chain leaders are gaining more influence on the international stage, especially in the optical module and PCB sectors, while also achieving breakthroughs in liquid cooling and power supply [1] - The AI-driven capital expenditure surge is creating challenges such as power shortages and storage deficits overseas, leading to heightened demand in domestic energy storage, gas turbines, and related industries [1] Company Holdings - The report lists significant stock holdings, including: - Zhongji Xuchuang: 2,035,762 shares valued at approximately 1.24 billion yuan - CATL: 2,330,228 shares valued at approximately 855.8 million yuan - Baiwei Storage: 5,872,779 shares valued at approximately 674.1 million yuan - Huiliang Technology: 35,830,178 shares valued at approximately 494.5 million yuan - WuXi Biologics: 13,464,500 shares valued at approximately 382.4 million yuan [3]

Group 1 - Three new healthcare-themed funds were launched on January 21, with fundraising amounts of 168 million, 75.87 million, and 10.01 million RMB respectively [1] - The launch of these funds indicates a growing interest among public fund institutions in the healthcare sector, with several firms filing for similar funds this year [1] - The advantages of the initiator funds include lower fundraising thresholds and a tighter alignment of interests between fund managers and investors, which can enhance management effectiveness [1] Group 2 - The healthcare sector has shown significant internal performance differentiation, with innovative drugs and export-related industries achieving notable excess returns [2] - Fund managers maintain an optimistic outlook for the healthcare industry, anticipating a gradual recovery in overall revenue growth by 2026, with a focus on innovative drug supply chains and medical outsourcing [2] - The innovative drug sector is transitioning from rapid imitation to differentiated innovation, with a marked increase in overseas licensing transactions by domestic pharmaceutical companies since 2020 [2] Group 3 - Investment strategies in the healthcare sector for 2026 will focus on innovation upgrades and domestic demand improvements [3] - The innovative drug and device investment opportunities are expected to continue, but investors will seek greater certainty, making stock selection more critical [3] - The traditional Chinese medicine sector is currently undervalued, presenting long-term investment potential, while certain segments of consumer healthcare and medical devices are beginning to recover [3]

Core Viewpoint - The new policy from the National Healthcare Security Administration (NHSA) is expected to significantly boost the medical device industry, particularly benefiting high-end surgical assistance technologies, robotic surgeries, and telemedicine [1][3]. Group 1: Market Reaction - A-share medical ETFs, particularly the largest medical ETF (512170), saw a rise of 1.36% during intraday trading, indicating strong buying interest with over 270 million yuan invested the previous day [1]. - The Hong Kong medical ETF (159137) also experienced a rebound, reaching a peak increase of 1.78% before closing up 1.06%, ending a four-day decline [1]. - Notable stock performances included a 17.3% surge in the leading domestic surgical robot company, MicroPort Scientific Corporation-B, and over 5% increases in MicroPort Medical and Xianjian Technology [1]. Group 2: Policy Impact - The NHSA's new guideline establishes a market mechanism for high-end surgical assistance technologies, which is expected to enhance innovation and profitability in the industry [3]. - The unified pricing framework is anticipated to highlight the cost-performance advantages of domestic surgical robots and related consumables, accelerating the trend of domestic substitution [3]. - The NHSA's commitment to expanding the guideline in the future will create more opportunities for innovative medical device products, benefiting the overall innovation ecosystem in the industry [3]. Group 3: Investment Opportunities - The medical device sector is poised for significant investment opportunities due to the new NHSA policy, with a focus on high-end medical equipment, robotic surgeries, and compliant consumables [3]. - The CXO industry is experiencing improved conditions due to recovering overseas orders and domestic capacity clearance, contributing to sustained growth [3]. - The largest medical ETF (512170) and its associated funds focus on medical devices and services, with over 36% of its index weight in AI medical and brain-computer interface concept stocks [4].

Core Insights - The 2025 Q4 report from Changcheng Pharmaceutical Industry Selected Fund indicates a "high-low-tail" oscillating upward pattern in A-shares, while H-shares are experiencing a consolidation phase, with December showing a significant underperformance compared to A-shares, driven by policy, liquidity, and profit expectations [1][3] Summary by Category Market Performance - A-shares exhibited a "high-low-tail" oscillating upward pattern in Q4 2025, while H-shares faced a consolidation phase, with December showing a notable underperformance against A-shares [1][3] - The performance of both markets is influenced by policy, liquidity, and profit expectations, with H-shares additionally pressured by overseas liquidity and funding preferences [1][3] Investment Strategy - The fund manager suggests that many innovative pharmaceutical stocks currently offer good value for money [1][3] - The investment strategy has been adjusted to form two allocation lines: "already BD" and "not yet BD" [1][3] - "Already BD" stocks focus on the importance of MNC internal pipelines and the global core clinical advancement rhythm, while "not yet BD" stocks are based on the global competitiveness and scarcity of core pipelines [1][3] - The strategy also considers the nearing end of the impact of centralized procurement on financial statements and the overall verification phase of innovative transformation for generic-to-innovative companies, leading to increased attention on these companies [1][3]

截至收盘，恒生指数报收26585.06点，上涨97.55点，涨幅0.37%。 昨晚，美股市场全线大跌，道指狂跌870点，纳指大跌561点，这也为今日（1月21日）港股表现蒙上阴 影。 不过，港股市场今日下午展开反攻，恒生科技指数涨超1%。 市场热点方面，机器人概念股全线走强。其中，微创机器人-B（HK02252）涨超17%，卧安机器人 （HK06600）涨超10%，优必选（HK09880）涨超4%。 资金方面，截至收盘，南向资金净买入港股超139亿港元。 展望后市： 华泰证券认为，当前推动一季度市场反弹的核心因素并未发生根本性变化，如金融条件整体偏宽松、外 资和南向共振回流、盈利预期上修、AH比价下港股性价比再度凸显等。尤其是考虑到目前市场对港股 后续表现尚未形成共识，一季度延续反弹依然可期，建议重点关注港股布局机会。行业上，现阶段重点 关注AI链（半导体、软件）及创新药。 华西证券预计，未来一段时间港股市场风格和2025年一季度和二季度风格相比出现进一步的转变，仍然 是2025年涨幅偏小、受外围市场影响较小、基本面韧性较好的资产存在一些结构性机会。 恒生科技指数报收5746.30点，上涨62.86点，涨幅1 ...

Core Insights - The current market environment in 2026 differs significantly from 2015, with the recent rise to 4100 points driven by solid industrial foundations and profit support rather than just liquidity and risk appetite [1][5][6] - Opportunities in the market are emerging from accelerated global AI capital expenditure, with Chinese companies actively participating in various segments of the AI industry chain [1][6] - The ongoing geopolitical tensions, abundant liquidity, and economic recovery are contributing to rising prices of upstream resources, creating new investment opportunities [1][6] Market Dynamics - The A-share market is transitioning from a phase primarily driven by liquidity and risk appetite to one where both profits and valuations are expected to drive growth [2][7] - Recent increases in retail investor participation have led to heightened market sentiment, necessitating regulatory measures to ensure stability [2][7] - Short-term market corrections may occur due to over-exuberance, but patience and careful stock selection are advised for investors [2][7] Sector Focus - Continued attention is recommended for sectors such as AI computing power, semiconductors, and export-oriented industries like non-ferrous metals, electric grid equipment, and engineering machinery [2][7] - In the context of inflationary pressures, sectors like innovative pharmaceuticals and non-bank financials are suggested for consideration [2][7] Thematic Investment Opportunities - AI applications and commercial aerospace are highlighted as attractive investment themes, particularly after recent adjustments that may have alleviated short-term overheating [3][8] - The commercial aerospace sector, supported by strong policy backing and macro narratives like SpaceX, is expected to see continued upward momentum [3][8] - High-risk investors are encouraged to identify quality leaders within these sectors during periods of adjustment for long-term gains [3][8]

Group 1 - The Hong Kong Technology ETF (513020) rose over 0.7% on January 21, with a focus on the AI industry as a key driver for future performance [1] - Major Hong Kong tech companies are accelerating the integration of AI into their business ecosystems, with Alibaba leveraging its Qianwen platform for product deployment in e-commerce and transportation, while Tencent is enhancing its WeChat ecosystem to promote AI mini-programs and applications in education [1] - The Hong Kong market is seeing a concentration of leading semiconductor companies, and the recent stable performance of domestic GPU, large model, and hard tech companies post-listing suggests a continued rhythm of quality tech firms going public in Hong Kong [1] Group 2 - The Hong Kong Technology Index has outperformed the Hang Seng Technology Index, particularly in sectors like new energy vehicles, innovative pharmaceuticals, and semiconductors, with a cumulative return of 224.25% from the end of 2014 to the end of 2025, exceeding the Hang Seng Technology Index's 83.87% by over 140% [2] - The Hong Kong Technology Index has consistently outperformed other indices, including the Hang Seng Internet Index, the Hang Seng Internet Technology Index, and the Hang Seng Healthcare Index [2]

Group 1 - The JPMorgan Healthcare Conference (JPM2026) commenced on January 12 in San Francisco, showcasing 24 Chinese innovative pharmaceutical companies through main stage presentations and Asia-Pacific sessions [1] - Notable companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech presented their latest research and commercialization achievements, alongside CXO companies like WuXi AppTec and WuXi Biologics [1] - The report titled "2026 Global M&A Annual Outlook" indicates that global M&A transaction volume surged to $5.1 trillion in 2025, with the healthcare sector leading with a 44% increase [1] Group 2 - Analysts predict that medium-sized transactions valued between $5 billion and $15 billion will remain active in 2026 [1] - The Hang Seng Biotechnology Index focuses on innovative drug "crown jewels," highlighting three main advantages: concentration of leading companies, scarcity of futures liquidity, and high elasticity & high Sharpe ratio [1] - Investors looking for convenient access to core leaders in innovative pharmaceuticals are encouraged to consider the Hang Seng Biotechnology ETF (520933) for streamlined investment [1]